News

PAH market narrows
Enlarge image

PharmaSwitzerlandGermany

PAH market narrows

24.10.2012 - The competition for PAH treatments will become fierce. Actelion and Bayer both plan to market new treatments for this rare disease.

Good news for PAH (pulmonal arterial hypertension) patients: two new drugs are planned for market release. The Swiss biotech Actelion submitted a new drug application to the FDA for its Opsumit macitentan treatment. The filing is based on data from a Phase III study, which proved to be able to reduce the risk of a morbidity or mortality event compared to placebo. A low-dose of Opsumit reduced the risk by 30%, while the high dose had a 45% reduction. The compound is a tissue-targeting endothelin receptor antagonist and is thought to replace revenues from Tracleer, Actelion’s best-seller which will lose patent protection in 2015.

At the same time as Actelion announced the application, German pharma Bayer AG announced that its compound riociguat met the primary endpoint in a Phase III study. The oral soluble guanylyl cyclase (sGC) stimulator led to an improvement in a six minute walk test enhancing the patient’s walk distance to 36 meters. Bayer plans to submit regulatory filing for riociguat in the first half next year. Analysts said that macitentan might become the next first-line treatment and expected high revenues. Riociguat however might become a second line option and get additional competition from Pfizer’s Sildenafil, which is already approved for PAH and acts via the same pathway.

© eurobiotechnews.eu/pd

http://www.european-biotechnology-news.com/news/news/2012-04/pah-market-narrows.html

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

ResearchUKSwitzerland

03.08.2014 In its efforts to become the leading country in genetic research, the UK has attracted investments worth more than £300m (€376m) to map 100,000 human genomes by 2017.

BusinessSpainUKSweden

31.07.2014 Astrazeneca is buying the rights to Almirall’s respiratory drugs in a deal worth up to €1.56bn.

BusinessFranceGermanySwitzerlandUK

30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SANTHERA74.95 CHF10.30%
  • BIOTEST80.50 EUR6.83%
  • WILEX2.22 EUR5.71%

FLOP

  • 4SC1.20 EUR-6.25%
  • VITA 343.78 EUR-2.83%
  • EPIGENOMICS3.12 EUR-2.50%

TOP

  • MAGFORCE6.50 EUR20.4%
  • LONZA101.10 CHF9.2%
  • SANTHERA74.95 CHF7.8%

FLOP

  • WILEX2.22 EUR-32.3%
  • VITA 343.78 EUR-20.1%
  • MOLOGEN7.80 EUR-17.5%

TOP

  • SANTHERA74.95 CHF3556.1%
  • CO.DON2.50 EUR228.9%
  • PAION2.40 EUR185.7%

FLOP

  • CYTOS0.27 CHF-93.3%
  • MEDIGENE4.60 EUR-66.4%
  • THERAMETRICS0.08 CHF-46.7%

No liability assumed, Date: 20.08.2014